Bladder Cancer Coverage from Every Angle


Propensity Matching Matters in Comparing Radiation Therapy and Radical Cystectomy
Update on Use of Perioperative Chemotherapy for High-Grade Upper Tract Urothelial Cancer
Targeting CDCP1 Cell-Surface Protein Via Radiotherapy in Metastatic Bladder Cancer
Phase II Trial Update on Potential Bladder-Sparing Treatment
ASCO GU 2023: Extended Follow-up From CheckMate 274 With Nivolumab for High-Risk Urothelial Carcinoma
Novel Targeted Aptamer-Drug Conjugate Under Study in Bladder Cancer
ASCO GU 2023: Update From KEYNOTE-057 on Pembrolizumab Monotherapy for Aggressive Bladder Cancer
ASCO GU 2023: Overall Survival Update From IMvigor130 on Atezolizumab Versus Chemotherapy for Advanced Urothelial Carcinoma
ASCO GU 2023: Predicting Outcomes With Enfortumab Vedotin in Advanced Urothelial Carcinoma
ASCO GU 2023: TROPHY-U-01 Update Supports Further Evaluation of Sacituzumab Govitecan in Urothelial Cancer
Prognostic Factors of Secondary Bladder Cancer After Radical Surgery for Urothelial Carcinoma
Study Finds Room for Improvement in Assessing Quality of Life in Patients With Bladder Cancer
Study Centers on Key Role of the E3 Ligase RFWD3 in Bladder Cancer
Can Decreased Nectin-4 Expression Predict Resistance to Enfortumab Vedotin in Urothelial Carcinoma?
Can a Genetic Signature Be Used to Predict Clinical Outcomes in Bladder Cancer?
A Novel Tool for Risk Assessment and Personalized Care for Patients With Bladder Cancer
Phase II TALASUR Trial to Study Maintenance Talazoparib Plus Avelumab in Urothelial Carcinoma
Methylation of PENK: Potential Biomarker for Early Detection of Bladder Cancer?
Rogaratinib Versus Chemotherapy for Advanced Urothelial Carcinoma: Phase II Trial Results
First Gene Therapy for High-Risk, Non–Muscle-Invasive Bladder Cancer Approved by the FDA
Shedding Research Light on the OAS Gene Family in Bladder Cancer
Can Single-Port Robotic Surgery Improve Cosmesis After Bladder Procedures?
Is Infection With Human Polyomavirus a Causative Factor in Bladder Cancer in Southern Iran?
Is Progression of Bladder Cancer Influenced by the KDELR2-KIF20A Axis? Researchers in China Say Yes
SITC 2022: Avelumab-Based Combination Therapy for Advanced Urothelial Carcinoma
Risk-Aligned Bladder Cancer Surveillance: Data-Driven Approach to Implementation Mapping
SITC 2022: Phase II Trial Update on Vaccine Plus Pembrolizumab in Resistant Bladder Cancer
ASTRO 2022: Comparison of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
ASTRO 2022: Can Genetic Mutations Determine Response to Trimodality Therapy in Bladder Cancer?
ASTRO 2022: Adding Pelvic Lymph Node Treatment to Bladder-Sparing Chemoradiotherapy for Bladder Cancer
ASTRO 2022: Radiotherapy Versus Surgery for Node-Positive, Nonmetastatic Bladder Cancer
The Role of Memory Immune and Effector Cells in Early Progression of Bladder Cancer
YAP1 Activation: A Potential Prognostic and Therapeutic Factor in Bladder Cancer
A Novel Gene Signature May Help Predict the Prognosis of Bladder Urothelial Carcinoma
Can Photodynamic-Guided Surgery in Non–Muscle-Invasive Bladder Cancer Reduce Recurrences?
Tislelizumab Plus Chemotherapy as First-Line Adjuvant Treatment of Advanced Bladder Cancer
Can Alternative Splicing Help to Reveal a Prognostic Biomarker in Muscle-Invasive Bladder Cancer?
Advanced Urothelial Carcinoma: Combination of Soluble EphB4-Human Serum Albumin Plus Pembrolizumab

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.